UnitedHealth Beats Estimates and Lifts Full-Year Outlook as Cost Discipline Holds
UnitedHealth Group reported third-quarter adjusted earnings of $4.69 a share, ahead of the $4.14 average analyst estimate compiled by LSEG and well above the $2.92 a year earlier. Revenue of $112.7 billion edged down from $113.2 billion but beat expectations of roughly $111 billion. The largest U.S. private insurer raised its full-year 2026 adjusted earnings outlook to at least $20.50 a share, from the prior range of $19.50 to $20.00 and above the $19.87 consensus.
The metric Wall Street watched most, the share of premiums spent on care, came in at 88.4% against 89.9% a year earlier and the 89.9% analysts had projected. Net medical reserve development was a favorable $610 million tied to 2026 dates of service. Consolidated operating income rose to $6.6 billion from $4.3 billion, the net margin was 3.6%, operating cash flow was $5.1 billion, and debt to capital stood at 41.7% on September 30.
Chief Executive Stephen Hemsley said the results "reflect the discipline and execution our teams are bringing to every part of our business," adding that the company is evolving toward a simpler, more supportive experience for patients and clinicians. The lower cost ratio was attributed to medical cost management initiatives, benefit design changes, pricing discipline and care delivery enhancements focused on affordability and integrated value-based care.
Chief Financial Officer Wayne DeVeydt told CNBC that medical costs "continue to be elevated versus historical norms," the issue that has dogged insurers running private Medicare Advantage plans for more than two years. He said technological investments have reduced the overall cost of delivering care, and described the quarter as continued execution "with a simpler approach" that invests heavily in value-based care, which pays doctors and facilities on patient outcomes rather than service volume.
DeVeydt pointed to evidence that treatment is moving to cheaper settings: acute hospital admissions among UnitedHealth members dropped 15% year over year through the third quarter, while home health admissions rose 10%. Combined with a shrinking membership base and exits from unprofitable contracts, that mix is how the company is defending margins while revenue drifts lower.
UnitedHealthcare's insurance business posted revenue of $86.3 billion, down from $87.1 billion, yet operating earnings climbed to $2.8 billion from $1.8 billion and the operating margin rose to 3.3% from 2.1%. The Medicaid-focused Community & State unit reported $23.7 billion against $23.8 billion. The company credited benefit changes, pricing, and medical and operating cost controls.
Optum served more than 120 million patients and consumers, with revenue of $66.9 billion and earnings of $3.7 billion. Optum Insight revenue rose 3% to $5.5 billion on operating earnings of $1.3 billion, versus $920 million a year earlier. Optum Rx earned $1.7 billion on $39.9 billion of revenue, up from $1.5 billion on $39.7 billion, though adjusted scripts fell to 393 million from 414 million as membership declined. The overall gain was driven largely by improved operations in the Optum Health clinical unit.
Not everything is fixed. Management has said commercial medical cost trend is running modestly above 11%, pushing full commercial margin recovery past 2027, and UnitedHealth is discontinuing Medicare Advantage plans covering roughly 390,000 members next year. TD Cowen cut its price target to $402 from $430 before the report, pointing to about $1.5 billion of revenue headwind in 2028 from lower Medicare star ratings.
For patients, a narrower plan lineup and changed benefit designs shift premiums and out-of-pocket exposure. For clinicians, value-based contracts tie pay to outcomes instead of volume. For investors, the guidance raise is the payoff, though options markets implied a 6.5% move around the print. The shares closed at $378.81 on October 9, up 2.12% that session and roughly 17% year to date.
The next test is whether the 88.4% cost ratio holds through the fourth quarter, whether the commercial trend cools, and how quickly Medicare Advantage contractions and star-rating cuts show up in reported revenue.